The Queen's University researchers demonstrated for the first time how molecular analysis of clinical trial biopsy samples can be used to help clinicians identify the key changes that occur in an individual patient's colorectal tumor prior to surgery, so clinicians can better understand and treat the disease. The study, published in the Journal of Pathology, hope that this 'personalised medicine' approach could ultimately improve the prognosis and quality of life for bowel cancer patients.
Dr. Philip Dunne, Senior Research Fellow from the Centre for Cancer Research and Cell Biology at Queen's explains, "There are approximately 1.4 million cases of bowel cancer diagnosed annually worldwide, with 41,000 cases in the UK each year. A number of treatment options are available but mortality rates remain high, with bowel cancer the second most common cause of cancer death in the UK.
"Advances in molecular and genetic analysis in the past 10 years have markedly improved our biological understanding of colorectal cancer, although this increased knowledge it is yet to significantly change standard patient care. This study highlights how we can begin to use this new understanding developed in research laboratories, to identify the biology underlying an individual patient's tumour in the clinic; the 'bench-to-bedside' approach."
Matthew Alderdice, a postdoctoral fellow on the project said, "Although molecular analysis is routinely carried out in research laboratories from large surgically removed tumours, in current clinical practice the tissue available for clinical decision-making may be only be the initial small tumour biopsy tissue. This study highlights how a precise understanding of the genetic changes that occur within this biopsy material is crucial to both understanding and treating the disease."
Professor Mark Lawler, Chair in Translational Cancer Genomics at Queen's said, "Molecular studies have indicated that a 'one size fits all' treatment approach for bowel cancer isn't a viable option if we are to effectively tackle this disease. We have demonstrated the ability of molecular classification systems to stratify patients based on their molecular make-up in a series of colorectal biopsy samples obtained during a phase II clinical trial."
"The ultimate aim of this work is to allow patients to receive a more tailored disease management plan based on the specific biology of their tumour. Thus, we can tailor treatment to the individual patient, maximising its effectiveness while minimising potential side effects." This research study is part of the Stratification in Colorectal Cancer (S:CORT) consortium led by Tim Maughan, Professor of Clinical Oncology at the University of Oxford.
"This work highlights the benefit of a UK wide approach, bringing together the collective expertise within our consortium to drive new approaches to improve bowel cancer outcomes. Our S:CORT Consortium is gaining new insights into the key factors that influence bowel cancer development and its treatment and using this knowledge to maximise best treatment and quality of life for bowel cancer patients," Professor Tim Maughan added.
Deborah Alsina MBE, Chief Executive of Bowel Cancer UK and Beating Bowel Cancer, the UK's leading bowel cancer charity and a partner in S:CORT, said: "We are delighted to be associated with this research. Our recent Critical Research Gaps in Colorectal Cancer Initiative highlighted the need for better research collaboration. This is an excellent example of the best UK science and clinical care in bowel cancer working together to develop innovative approaches to save more lives."